A molecular pathway analysis of the glutamatergic–monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment

Antonio Drago, Enrico Cocchi, Concetta Crisafulli, Alessandro Serretti

Research output: Contribution to journalArticle


The efficacy of current antidepressant (AD) drugs for the treatment of major depressive disorder (MDD) lays behind expectations. The correct genetic differentiation between severe and less severe cases before treatment may pave the way to the most correct clinical choices in clinical practice. Genetics may pave the way such identification, which in turns may provide perspectives for the synthesis of new ADs by correcting the molecular unbalances that differentiate severe and less severe depressive patients. We investigated 1,903 MDD patients from the STAR*D study. Outcome was the number of severe depressive records, defined as a Quick Inventory of Depressive Symptomatology (QIDS)-Clinician rated (C) total score >15, corrected for the number of observations for each patient during the first 14 weeks of citalopram treatment. Predictors were the genetic variations harbored by genes involved in the glutamatergic–monoaminergic interplay as defined in a previous work published by our group. Clinical and socio-demographic stratification factor analyses were taken in cases and controls. Covariated linear regression was the statistical model for the analysis. SNPs were analyzed in groups (molecular pathway analysis) testing the hypothesis that the distribution of significant (p 

Original languageEnglish
Pages (from-to)465-475
Number of pages11
JournalJournal of Neural Transmission
Issue number3
Publication statusPublished - 2015



  • Citalopram
  • Glutamatergic
  • Major depressive disorder
  • Molecular pathways
  • Monoaminergic

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this